Serum Protein Profiles in Carcinoma of the Kidney

Richards, B.; Robinson, M.R.G.; Pidcock, N.B.; Cooper, Edward H.

doi:10.1159/000473474

Cited by 18 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier reports on serum B2-M in renal cell carcinoma only presented a limited number of patients (13,19). Selli et al (13) found increased levels of P2-M compared with controls.…”

Section: Discussionmentioning

confidence: 96%

Serum β₂-Microglobulin and Prognosis of Patients with Renal Cell Carcinoma

1996

View full text Add to dashboard Cite

“…Earlier reports on serum B2-M in renal cell carcinoma only presented a limited number of patients (13,19). Selli et al (13) found increased levels of P2-M compared with controls.…”

Section: Discussionmentioning

confidence: 96%

Serum β₂-Microglobulin and Prognosis of Patients with Renal Cell Carcinoma

1996

View full text Add to dashboard Cite

“…However, there are no known accurate tumor markers that are specific enough for diagnosis or monitoring the postoperative course of the patients with RCC. C-reactive protein [2], lipid-associated sialic acid [3], carcinoembryonic antigen [4], renin, haptoglobulins [5], plasma fibrinogen [6] and erythropoietin [7] are some of the proposed biological markers. Ferritin is one of the major proteins of iron metabolism which is demonstrated to be elevated in the serum of patients with RCC and is suggested as a serum marker [8,9].…”

mentioning

confidence: 99%

Serum Ferritin as a Clinical Markerfor Renal Cell Carcinoma: Influenc e of Tumor Size and Volume

Kırkalı¹,

Güzelsoy²,

Mungan³

et al. 1999

Urol Int

View full text Add to dashboard Cite

Objectives: There is no established tumor marker for renal cell carcinoma (RCC). Ferritin is shown to be expressed by the tumor, and proposed as a tumor marker. The aim of this study is to assess the relation between ferritin levels and tumor volume, size and prognosis in RCC. Methods: We studied ferritin levels in serum from peripheral and renal veins of 52 patients with RCC who underwent surgery. Ferritin levels were measured by an enzyme immunoassay method. Tumor volume and the largest tumor diameter were calculated from the pathologic specimens. Results: The mean serum ferritin level from the renal vein (RVF) was statistically higher than the ferritin level from the peripheral vein (PVF) (p = 0.028). Although mean RVF level increased with increasing stage, it was not significant. While there was a correlation with tumor size, volume and RVF, PVF was in correlation with disease status. PVF in patients with metastatic and/or locally advanced disease was significantly higher than the patients with localized disease (p = 0.023). The initial RVF and PVF levels were predictive of survival (p = 0.028 and p = 0.034, respectively). Conclusions: Higher levels in the renal vein, its positive correlation with tumor size and volume suggest that ferritin is expressed by RCC. Initial peripheral serum values of ferritin can be indicative of disease status and also be a prognosticator of survival.

show abstract

The role of C-reactive protein and polyarginine in tumor immunotherapy

Rizk

Mold

Haklin

et al. 1986

Cancer

View full text Add to dashboard Cite

C-reactive protein (CRP) is an acute-phase reactant whose serum level rises rapidly in response to tissue injury. C-reactive protein binding to cells can activate the classical complement pathway, and enhance opsonophagocytosis. The polycation poly-L-arginine (PLA) can artificially fix CRP to target cells. The effects of CRP and PLA on tumor growth were evaluated, both independently and synergistically, using the V X 2 tumor line in the rabbit host. Ten normal animals and seven acute-phase animals were bilaterally inoculated with V X 2 cells (control side) and PLA-treated V X 2 cells (experimental side). Tumor growth was significantly retarded on the treatment side (P less than 0.005), in both animal groups. It is concluded that topical PLA is a potent inhibitor of V X 2 tumor growth. Comparison of normal and acute-phase animals revealed no persistent difference in tumor growth for either cell inoculum. Similarly, cell treatment with topical CRP did not inhibit tumor growth, whether PLA was present or not. Thus, circulating and topical CRP did not alter the rate of V X 2 tumor growth. PLA cytotoxicity remains to be evaluated when the agent is administered orthotopically, selectively, or systemically.

show abstract

Serum Protein Profiles in Carcinoma of the Kidney

Cited by 18 publications

References 8 publications

Serum β₂-Microglobulin and Prognosis of Patients with Renal Cell Carcinoma

Serum β₂-Microglobulin and Prognosis of Patients with Renal Cell Carcinoma

Serum Ferritin as a Clinical Markerfor Renal Cell Carcinoma: Influenc e of Tumor Size and Volume

The role of C-reactive protein and polyarginine in tumor immunotherapy

Contact Info

Product

Resources

About

Serum Protein Profiles in Carcinoma of the Kidney

Cited by 18 publications

References 8 publications

Serum β2-Microglobulin and Prognosis of Patients with Renal Cell Carcinoma

Serum β2-Microglobulin and Prognosis of Patients with Renal Cell Carcinoma

Serum Ferritin as a Clinical Markerfor Renal Cell Carcinoma: Influenc e of Tumor Size and Volume

The role of C-reactive protein and polyarginine in tumor immunotherapy

Contact Info

Product

Resources

About

Serum β₂-Microglobulin and Prognosis of Patients with Renal Cell Carcinoma

Serum β₂-Microglobulin and Prognosis of Patients with Renal Cell Carcinoma